Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H2 Market Research Report 2017

Posted on 2017-09-01 by Mark Hub in Healthcare // 0 Comments

Albany, US, 2017-Sep-01 — /EPR Network/ —Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H2 2017”. Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.

Request For Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1313675

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 3, 1, 23, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology).
– The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Browse Full Report With TOC: http://www.marketresearchhub.com/report/chemotherapy-induced-peripheral-neuropathy-pipeline-review-h2-2017-report.html

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Peripheral Neuropathy – Overview
Chemotherapy Induced Peripheral Neuropathy – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chemotherapy Induced Peripheral Neuropathy – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chemotherapy Induced Peripheral Neuropathy – Companies Involved in Therapeutics Development
Achelios Therapeutics Inc
Advinus Therapeutics Ltd
Apollo Endosurgery Inc
Aptinyx Inc
Asahi Kasei Pharma Corp
Can-Fite BioPharma Ltd
Celgene Corp
Eisai Co Ltd
Immune Pharmaceuticals Inc
Insys Therapeutics Inc
Kineta Inc
KPI Therapeutics Inc
Krenitsky Pharmaceuticals Inc
Midatech Pharma US Inc
Mundipharma International Ltd
Nemus Bioscience Inc
Neurocentrx Pharma Ltd
Panacea Pharmaceuticals Inc
PeriphaGen Inc
PledPharma AB
Sova Pharmaceuticals Inc
Trevena Inc
WEX Pharmaceuticals Inc
Chemotherapy Induced Peripheral Neuropathy – Drug Profiles
(amitriptyline + ketamine hydrochloride) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-1083 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-1710 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-2009 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-3330 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BR-297 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimiracetam – Drug Profile

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1313675

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick